Literature DB >> 8928736

Evidence for receptor-mediated mineralocorticoid action in rat osteoblastic cells.

M K Agarwal1, F Mirshahi, M Mirshahi, S Bracq, J Chentoufi, M Hott, A Jullienne, P J Marie.   

Abstract

Aldosterone significantly enhanced the proliferation of osteoblastic cells from rat calvaria, and this effect was inhibited by RU 26752 and ZK 91587, two antagonists specific to the mineralocorticoid receptor (MCR). In addition, aldosterone inhibited the activity of alkaline phosphatase, a marker of the osteoblastic phenotype, and this effect was also reversed by RU 26752. Cytoplasmic staining of MCR was observed in rat calvaria osteoblasts incubated with a specific polyclonal antiserum raised against rat kidney MCR. This anti-MCR immunoglobulin G immunoprecipitated and macroaggregated the MCR-[3H]RU 26752 complex in osteoblastic cytosol. A single 98-kDa band was observed when osteoblastic cytosol was analyzed by Western blotting with anti-MCR serum. The 98-kDa band was also obtained after autoradiography of irradiated osteoblastic cytosol-[3H]R 5020 complex, and this was abolished in the presence of RU 26752. A p26MR probe, specific to COOH-terminal end of MCR, hybridized with the predicted product after amplification of total cell RNA by polymerase chain reaction technique. Furthermore, hybridization of poly(A)+ mRNA from at calvaria osteoblastic cells with the p26MR probe revealed a major band of approximately 4.2 kb. Collectively, our studies demonstrate the existence of a functional MCR in rat calvaria osteoblasts.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8928736     DOI: 10.1152/ajpcell.1996.270.4.C1088

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  4 in total

Review 1.  Genetic approaches to determine the role of glucocorticoid signaling in osteoblasts.

Authors:  John R Harrison; Henning W Woitge; Barbara E Kream
Journal:  Endocrine       Date:  2002-02       Impact factor: 3.633

2.  Vertebral fractures assessed with dual-energy X-ray absorptiometry in patients with Addison's disease on glucocorticoid and mineralocorticoid replacement therapy.

Authors:  Valentina Camozzi; Corrado Betterle; Anna Chiara Frigo; Veronica Zaccariotto; Martina Zaninotto; Erica De Caneva; Paola Lucato; Walter Gomiero; Silvia Garelli; Chiara Sabbadin; Monica Salvà; Miriam Dalla Costa; Marco Boscaro; Giovanni Luisetto
Journal:  Endocrine       Date:  2017-08-09       Impact factor: 3.633

Review 3.  Adrenocortical incidentalomas and bone: from molecular insights to clinical perspectives.

Authors:  Barbara Altieri; Giovanna Muscogiuri; Stavroula A Paschou; Andromachi Vryonidou; Silvia Della Casa; Alfredo Pontecorvi; Martin Fassnacht; Cristina L Ronchi; John Newell-Price
Journal:  Endocrine       Date:  2018-08-02       Impact factor: 3.633

4.  Bone health and aldosterone excess.

Authors:  L Ceccoli; V Ronconi; L Giovannini; M Marcheggiani; F Turchi; M Boscaro; G Giacchetti
Journal:  Osteoporos Int       Date:  2013-05-22       Impact factor: 4.507

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.